|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Supplementary Table 1.** Association of additional combined markers identifying basal and luminal subtypes with clinical complete response to chemotherapy | | | | | |
| **Potential combined markers** | **CR**  **(*n*=20)** | **No CR**  **(*n*=43)** | | **Odds ratio (95% CI)** | ***P*** |
| **% of patients with covariate** | | |
| **Basal subtype** | | | | | |
| KRT5/6(+)/GATA3(-) | 15.0 | | 2.3 | 7.41 (0.72-76.34) | 0.092 |
| KRT14(+)/KRT20(-) | 15.0 | | 2.3 | 7.41 (0.72-76.35) | 0.092 |
| KRT14(+)/GATA3(-) | 10.0 | | 2.3 | 4.66 (0.40-54.79) | 0.220 |
| **Luminal subtype** | | | | | |
| GATA3(+)/KRT5/6(-) | 25 | | 32.6 | 0.69 (0.21-2.28) | 0.544 |
| KRT20(+)/KRT14(-) | 45.0 | | 51.2 | 0.78 (0.27-2.26) | 0.649 |
| GATA3(+)/KRT14(-) | 70 | | 79.1 | 0.62 (0.18-2.06) | 0.434 |
|  | | | | | |